The HCPLive dermatology page is a resource for medical news and expert insights on skin disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for dermatologic conditions, and more.
April 29th 2024
A new study found a 2-week mindfulness-based intervention for patients with psoriasis does not improve skin status—it only helps the mind.
Show Me Your Care Plan™: Nursing Considerations for Applying the Latest Approaches Across Care Settings in Melanoma
View More
Advances In: Integrating New Treatment Options into Management Plans for Patients with Moderate-to-Severe Atopic Dermatitis
View More
Medical Crossfire®: Maximizing Patient Outcomes in Shingles – Are You Leveraging Guideline Based Care?
View More
"REEL" Time Patient Counseling™: Integrating Biosimilars into the Clinical Conversation
View More
PER Skin Summit: Optimizing Diagnosis and Individualizing Management of Hidradenitis Suppurativa
View More
Advances In™: Aligning Pathology and Oncology Efforts in the Community to Improve NSCLC Care
View More
Community Practice Connections™: 19th Annual International Symposium on Melanoma and Other Cutaneous Malignancies®
View More
Expert Illustrations & Commentaries™: A Deeper Look at the Pathogenesis of Hidradenitis Suppurativa (HS)
View More
Cancer Summaries and Commentaries™: Clinical Updates in Melanoma from Philadelphia
View More
Medical Crossfire®: Where Are We in the World of ADCs? From HER2 to CEACAM5, TROP2, HER3, CDH6, B7H3, c-MET and Beyond!
View More
Expert Illustrations & Commentaries™: Picturing the Potential Role of OX40 and OX40L Inhibitors in Atopic Dermatitis
View More
Hidradenitis Suppurativa (HS): Deepening Foundations of Knowledge in Disease Pathogenesis, Disease Severity Assessment, and Treatment Decision-Making
View More
Tumor-Infiltrating Lymphocyte Therapy Advances Into Melanoma
View More
Crisaborole Ointment: a Novel, Nonsteroidal Atopic Dermatitis Treatment for Children and Adults
In the past 15 years, no new topical AD treatments have been approved. Crisaborole, however, could be an efficient, safe, non-steoidal treatment option, according to the results of two recent phase III studies.
Trial Shows Ixekizumab Effective Against Psoriatic Arthritis
Ixekizumab patients, who all started with an introductory 160-mg dose, were all more likely than placebo patients to achieve the primary endpoint of the study: a 20% reduction in disease burden as measured by American College of Rheumatology criteria (an ACR20 response) by week 24.
Jerry Bagel: Discussing Treatment Options with Patients
As newer treatment options hit the market for plaque psoriasis patients may have more questions about the best options for them. This is part of the importance of communicating with patients throughout the treatment process.
Jerry Bagel: Approaching Psoriasis Treatment Based on Location
As with many conditions, the kind of care a patient receives can depend on where they live. This can be especially true for dermatology patients needing things like phototherapy. Other factors, like cost and fear, can also impede the treatment process.
Jerry Bagel: Research in Eczema Is Lacking, Despite Progress in Psoriasis
Despite the life of a patient with eczema being in many ways similar to that of a patient with psoriasis, their options for treatment are not nearly as robust as the other dermatologic condition.
Jerry Bagel, MD, Explains How to Measure Success in Psoriasis Treatment
As patients go through the process of treating their plaque psoriasis, there can be different levels of success depending on a number of situations. As a result, measuring success can be a challenge as well.
Jerry Bagel, MD: Evolution of Psoriasis Treatment Means Better Results for Patients
As new treatments for plaque psoriasis are developed the field as a whole is taking a new look at the condition. However, there are still challenges to overcome in diagnosis and treatment.
Biosimilar of Enbrel, a Popular Arthritis and Inflammation Drug, Receives FDA Approval
Erelzi, a biosimilar of Enbrel (etanercept), has received FDA approval. Biosimilars are defined by the organization as being “highly similar to an FDA-approved biological product†while demonstrating “clinically meaningful differences in terms of safety and effectiveness.â€
Psoriasis Severity Escalates Risk for Aortic Aneurysm
While it has been known for some time that psoriasis patients are at increased risk of developing cardiovascular disease and other comorbidities, new research has shown that these patients also have a higher risk of developing aortic aneurysms.
Most Patients with Plaque Psoriasis Are Dissatisfied with Their Treatment
Many psoriasis patients wish they were better informed of the significant impact their skin condition would have on their physical and mental health, according to results from Psoriasis in America 2016, a Health Union national survey.
Analysis of data from 2 large trials finds that cutoffs used to separate different “disease activity states†on the Disease Activity index for Psoriatic Arthritis (DAPSA) are valid. Different disease activity states are associated with different degrees of functional impairment and joint damage progression.